As the debate over Avandia enters its second day, more controversy is sure to erupt. With both sides clinging to inexplicable minutiae as much as they are to the major points defining this hefty FDA review, the outcome will probably say a lot about the process that leads to it. The latest salvos from Day 1?

An FDA scientist, speaking of GSK’s studies of the drug minimizing risk: You can’t trust it, and if we do trust it, we’re engaging in the willing suspension of disbelief.

GSK’s VP of Clinical Development: Our studies provide the most robust and reliable data  to assess Avandia’s safety, and those studies have found no evidence to suggest the drug increases the risk of heart attack or stroke in its users.

Testimony continues today with a decision expected on whether to pull the drug or apply restrictions to its use.

Related Posts Within Doctor Pundit:

1. Diabetes Drug Once Again under Scrutiny A couple of weeks before the FDA meets to discuss...
2. FDA to Decide Fate of Diabetes Drug This Week It’s official. The FDA will convene this Tuesday (13) to...
3. Report: Pharma Company Covered Up Known Cardiovascular Risks of Drug GSK (then known as SmithKline Beecham) knew in a 1999...
4. FDA: Avandia Stays on Market The vote is 20-12 against withdrawing GSK’s troubled drug Avandia...
5. FDA: Keep Avandia on Market, Impose Ponderous Restrictions on Use The FDA has announced today Avandia’s official indication. After months...